Home > News > Venture firms still don't see the nanotech in biosciences
October 1st, 2003
Venture firms still don't see the nanotech in biosciences
Timing is everything, say Oregon's venture fund managers. The state of nanotechnology in the biosciences is too early for venture capital investing, believes Gerry Langeler, of Seattle-based OVP Venture Partners, the oldest venture firm in the Pacific Northwest, currently with $195 million to invest.
TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014
Arrowhead Issues Open Letter to Shareholders October 9th, 2014
PEN Inc. Announces New Trading Symbol: PENC: Stock Continues Trading on the OTCQB September 3rd, 2014
Aspen Aerogels, Inc. to Present at Barclays CEO Energy-Power Conference August 27th, 2014